Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 118

Results For "SEC"

3011 News Found

7th India-Japan medical product regulatory symposium held at New Delhi
Policy | July 14, 2024

7th India-Japan medical product regulatory symposium held at New Delhi

Enhanced collaboration under the Memorandum of Cooperation (MoC) between India and Japan in medical product regulations


Lilly to acquire Morphic to improve outcomes for patients with inflammatory bowel disease
News | July 10, 2024

Lilly to acquire Morphic to improve outcomes for patients with inflammatory bowel disease

Acquisition to expand Lilly's immunology pipeline with oral integrin therapies


Olverembatinib approved for commercialization in Macau China
Drug Approval | July 09, 2024

Olverembatinib approved for commercialization in Macau China

Olverembatinib, a novel drug developed by Ascentage Pharma with support from the National Major New Drug Development program


Aster Health Academy announces strategic partnerships with premier Hospitals across India
News | July 08, 2024

Aster Health Academy announces strategic partnerships with premier Hospitals across India

The academy has secured partnerships with 15 esteemed hospitals


Health Minister Nadda visits the AIIMS Jammu
News | July 08, 2024

Health Minister Nadda visits the AIIMS Jammu

AIIMS Jammu is a beacon of hope not only for the people of J&K, but also for that of Leh, and other neighboring states


Increasing public awareness on World Zoonoses Day
News | July 08, 2024

Increasing public awareness on World Zoonoses Day

India boasts the largest livestock population, with 536 million livestock and 851 million poultry


Viatris closes divestitures of OTC business
News | July 08, 2024

Viatris closes divestitures of OTC business

Achievement of This Major Milestone Further Simplifies and Strengthens the Company and Positions Viatris to Achieve its Key Priorities and Accelerate Future Growth


Nephro Care India lists at 90% premium
News | July 06, 2024

Nephro Care India lists at 90% premium

NCIL was listed at Rs. 171 at an upper circuit premium of 90% over the fixed price band of Rs. 90


Merck inks MoU with Afrigen Biologics for development of mRNA vaccine technology platform
News | July 05, 2024

Merck inks MoU with Afrigen Biologics for development of mRNA vaccine technology platform

Aim of the collaboration is to develop mRNA platform technology, scale up and troubleshoot challenges in mRNA process optimization


GSK and CureVac restructure collaboration into new licensing agreement
News | July 05, 2024

GSK and CureVac restructure collaboration into new licensing agreement

CureVac receives €400 million upfront and up to an additional €1.05 billion in development, regulatory and sales milestone payments as well as tiered royalties; all previous financial considerations from the prior collaboration agreement replaced